{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-031199","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-09-25T17:05:32+00:00","discovered_at":"2026-09-25T17:06:01.582832+00:00","generated_at":"2026-10-12T13:20:53.870382+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Moleculin preclinical data: Annamycin pancreatic cancer activity partly mediated by CD8+ T cells","bullets":["Preclinical data: Annamycin's pancreatic cancer activity is partially mediated by CD8+ T cells, suggesting an immune-mediated mechanism beyond direct cytotoxicity.","Data presented at AACR Conference on Pancreatic Cancer, Sept 25–28, 2026, at Hilton San Diego Bayfront; abstract published in Sept 15, 2026 Cancer Research supplement.","Presenter: Angela T. Alistar, MD (Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center); abstract title: 'Turning cold pancreatic tumors hot'.","Annamycin is not currently in clinical development for pancreatic cancer; lead program remains MIRACLE trial in relapsed/refractory AML, the basis of near-term milestones.","CEO Walter Klemp: data point to 'unexpected additional benefit'; if observation holds, it broadens where Annamycin might be useful and how it might be combined."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-031199","json":"https://secwatch.observer/filing/0001437749-26-031199.json","markdown":"https://secwatch.observer/filing/0001437749-26-031199.md","text":"https://secwatch.observer/filing/0001437749-26-031199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/0001437749-26-031199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/mbrx20260924_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:20:53.870382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}